DBAG Fund VIII, a fund managed by Deutsche Beteiligungs (DBAG), acquired the Hipp Technology Group, a development partner and medical technology contract manufacturer, from an investor group represented by Endura. In connection with the deal,
Tags :Nicolas Mosimann
Pictet Alternative Advisors’ direct private equity investments team has entered into a strategic partnership with Tretor, an accounting services provider based in Liestal, with a branch office in Basel. In connection with the deal, Bä
Kellerhals Carrard advised Lakera – a AI Swiss startup founded by entrepreneurs David Haber, Matthias Kraft, and Mateo Rojas-Carulla – as well as early investors in the company Atomico and Redalpine, on the sale to NASDAQ-listed cybersecurity
Swiss precision medicines company Haya Therapeutics completed a $65 million series A funding round. In connection with the deal, Kellerhals Carrard represented lead investors Sofinnova Partners and Earlybird Venture Capital, while Lenz & Staehelin assisted Eli
Kellerhals Carrard advised Swiss clinical-stage biotechnology company MoonLake Immunotherapeutics on a debt funding deal with American venture lending specialist Hercules Capital, which was instead represented by Schellenberg Wittmer, acting as Swiss legal counsel. The deal
Kontivia Beteiligungen, a Zurich based long term oriented investment firm advised by Kellerhals Carrard, led a group of swiss entrepreneurial families, advised by Baker McKenzie, in the acquisition of a majority stake in Walter Meier (
Novartis hands over the Life-Science-Park Rhine Valley to GETEC Switzerland, the platform of a leading European energy supplier and contracting specialist GETEC Group. They are the new owner and operator of the properties and infrastructure
Kellerhals Carrard has reorganised and strengthened its Life Sciences team. It is now fully integrated into the value chain of its clients in the pharmaceutical, medical technology, health and nutrition sectors and is led by
Biognosys and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in the company. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has
